Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
NCT ID: NCT01336023
Last Updated: 2018-02-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1663 participants
INTERVENTIONAL
2011-05-23
2012-11-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
NCT01392573
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
NCT02773368
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
NCT02298192
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
NCT02420262
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
NCT01664247
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IDeg
insulin degludec
Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
IDegLira
insulin degludec/liraglutide
Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
Lira
liraglutide
Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
insulin degludec/liraglutide
Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
insulin degludec
Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
liraglutide
Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c 7.0-10.0 % (both inclusive) with the aim of a median HbA1c of 8.3%. Accordingly, when approximately 50% of the randomised subjects have a HbA1c above 8.3%, the remaining subjects randomised must have a HbA1c of below or equal to 8.3%, or when approximately 50% of the randomised subjects have a HbA1c of below or equal to 8.3%, the remaining subjects randomised must have a HbA1c above 8.3%
* Male or female, age 18 years or above (Taiwan: 20 years or above for a site 653 in Taiwan: Taichung Veterans General Hospital)
* Subjects on stable dose of 1-2 OADs (metformin \[at least 1500 mg or max tolerated dose\] or metformin \[at least 1500 mg or max tolerated dose\] + pioglitazone \[at least 30 mg\]) for at least 90 days prior to screening
* Body Mass Index (BMI) maximum 40 kg/m\^2
Exclusion Criteria
* Treatment with GLP-1 (glucagon-like peptide-1) receptor agonists (eg exenatide, liraglutide), sulphonylurea or dipeptidyl peptidase 4 (DPP-4) inhibitors within 90 days prior to trial
* Impaired liver function, defined as alanine aminotransferese (ALAT) at least 2.5 times Upper Normal Range (UNR) (one retest analysed at the central laboratory within a week from first sample taken is permitted with the result of the last sample being the conclusive)
* Impaired renal function defined as serum-creatinine at least 133 mcmol/l (at least 1.5 mg/dl) for males and at least 125 mcmol/l (at least 1.4) for females, or as allowed according to local contraindications for metformin (one retest analysed at the central laboratory within a week from first sample taken is permitted with the result of the last sample being the conclusive)
* Screening calcitonin at least 50 ng/L
* Subjects with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
* Cardiac disorder defined as: congestive heart failure (NYHA class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the last 12 months and planned coronary, carotid or peripheral artery revascularisation procedures
* Severe uncontrolled treated or untreated hypertension (systolic blood pressure at least 180 mm Hg or diastolic blood pressure at least 100 mm Hg)
* Acute treatment required proliferative retinopathy or maculopathy (macular oedema)
* History of chronic pancreatitis or idiopathic acute pancreatitis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Birmingham, Alabama, United States
Novo Nordisk Investigational Site
Anaheim, California, United States
Novo Nordisk Investigational Site
Bermuda Dunes, California, United States
Novo Nordisk Investigational Site
Concord, California, United States
Novo Nordisk Investigational Site
Encino, California, United States
Novo Nordisk Investigational Site
Fair Oaks, California, United States
Novo Nordisk Investigational Site
Fresno, California, United States
Novo Nordisk Investigational Site
Greenbrae, California, United States
Novo Nordisk Investigational Site
La Jolla, California, United States
Novo Nordisk Investigational Site
Long Beach, California, United States
Novo Nordisk Investigational Site
Los Angeles, California, United States
Novo Nordisk Investigational Site
Montclair, California, United States
Novo Nordisk Investigational Site
Monterey, California, United States
Novo Nordisk Investigational Site
Orange, California, United States
Novo Nordisk Investigational Site
Poway, California, United States
Novo Nordisk Investigational Site
San Diego, California, United States
Novo Nordisk Investigational Site
San Diego, California, United States
Novo Nordisk Investigational Site
San Diego, California, United States
Novo Nordisk Investigational Site
San Mateo, California, United States
Novo Nordisk Investigational Site
Santa Barbara, California, United States
Novo Nordisk Investigational Site
Tustin, California, United States
Novo Nordisk Investigational Site
Valencia, California, United States
Novo Nordisk Investigational Site
Walnut Creek, California, United States
Novo Nordisk Investigational Site
Colorado Springs, Colorado, United States
Novo Nordisk Investigational Site
Denver, Colorado, United States
Novo Nordisk Investigational Site
Golden, Colorado, United States
Novo Nordisk Investigational Site
Waterbury, Connecticut, United States
Novo Nordisk Investigational Site
Newark, Delaware, United States
Novo Nordisk Investigational Site
Clearwater, Florida, United States
Novo Nordisk Investigational Site
Delray Beach, Florida, United States
Novo Nordisk Investigational Site
Fort Lauderdale, Florida, United States
Novo Nordisk Investigational Site
Hialeah, Florida, United States
Novo Nordisk Investigational Site
Jacksonville, Florida, United States
Novo Nordisk Investigational Site
Kissimmee, Florida, United States
Novo Nordisk Investigational Site
Melbourne, Florida, United States
Novo Nordisk Investigational Site
Miami, Florida, United States
Novo Nordisk Investigational Site
Miami, Florida, United States
Novo Nordisk Investigational Site
Orlando, Florida, United States
Novo Nordisk Investigational Site
Pembroke Pines, Florida, United States
Novo Nordisk Investigational Site
Tampa, Florida, United States
Novo Nordisk Investigational Site
Atlanta, Georgia, United States
Novo Nordisk Investigational Site
Columbus, Georgia, United States
Novo Nordisk Investigational Site
Conyers, Georgia, United States
Novo Nordisk Investigational Site
Decatur, Georgia, United States
Novo Nordisk Investigational Site
Lawrenceville, Georgia, United States
Novo Nordisk Investigational Site
Roswell, Georgia, United States
Novo Nordisk Investigational Site
Woodstock, Georgia, United States
Novo Nordisk Investigational Site
Meridian, Idaho, United States
Novo Nordisk Investigational Site
Nampa, Idaho, United States
Novo Nordisk Investigational Site
Avon, Illinois, United States
Novo Nordisk Investigational Site
Chicago, Illinois, United States
Novo Nordisk Investigational Site
Gurnee, Illinois, United States
Novo Nordisk Investigational Site
O'Fallon, Illinois, United States
Novo Nordisk Investigational Site
Fishers, Indiana, United States
Novo Nordisk Investigational Site
Franklin, Indiana, United States
Novo Nordisk Investigational Site
Indianapolis, Indiana, United States
Novo Nordisk Investigational Site
Michigan City, Indiana, United States
Novo Nordisk Investigational Site
Muncie, Indiana, United States
Novo Nordisk Investigational Site
Crestview Hills, Kentucky, United States
Novo Nordisk Investigational Site
Lexington, Kentucky, United States
Novo Nordisk Investigational Site
Metairie, Louisiana, United States
Novo Nordisk Investigational Site
Metairie, Louisiana, United States
Novo Nordisk Investigational Site
Hyattsville, Maryland, United States
Novo Nordisk Investigational Site
North East, Maryland, United States
Novo Nordisk Investigational Site
Rockville, Maryland, United States
Novo Nordisk Investigational Site
Buckley, Michigan, United States
Novo Nordisk Investigational Site
Southfield, Michigan, United States
Novo Nordisk Investigational Site
Southfield, Michigan, United States
Novo Nordisk Investigational Site
Troy, Michigan, United States
Novo Nordisk Investigational Site
Chesterfield, Missouri, United States
Novo Nordisk Investigational Site
Kansas City, Missouri, United States
Novo Nordisk Investigational Site
Saint Charles, Missouri, United States
Novo Nordisk Investigational Site
Henderson, Nevada, United States
Novo Nordisk Investigational Site
Las Vegas, Nevada, United States
Novo Nordisk Investigational Site
Nashua, New Hampshire, United States
Novo Nordisk Investigational Site
Flemington, New Jersey, United States
Novo Nordisk Investigational Site
Toms River, New Jersey, United States
Novo Nordisk Investigational Site
Toms River, New Jersey, United States
Novo Nordisk Investigational Site
Albany, New York, United States
Novo Nordisk Investigational Site
Northport, New York, United States
Novo Nordisk Investigational Site
Syracuse, New York, United States
Novo Nordisk Investigational Site
The Bronx, New York, United States
Novo Nordisk Investigational Site
West Seneca, New York, United States
Novo Nordisk Investigational Site
Asheboro, North Carolina, United States
Novo Nordisk Investigational Site
Asheville, North Carolina, United States
Novo Nordisk Investigational Site
Burlington, North Carolina, United States
Novo Nordisk Investigational Site
Chapel Hill, North Carolina, United States
Novo Nordisk Investigational Site
Charlotte, North Carolina, United States
Novo Nordisk Investigational Site
Greensboro, North Carolina, United States
Novo Nordisk Investigational Site
Greenville, North Carolina, United States
Novo Nordisk Investigational Site
Morehead City, North Carolina, United States
Novo Nordisk Investigational Site
Shelby, North Carolina, United States
Novo Nordisk Investigational Site
Statesville, North Carolina, United States
Novo Nordisk Investigational Site
Winston-Salem, North Carolina, United States
Novo Nordisk Investigational Site
Canton, Ohio, United States
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States
Novo Nordisk Investigational Site
Cleveland, Ohio, United States
Novo Nordisk Investigational Site
Columbus, Ohio, United States
Novo Nordisk Investigational Site
Franklin, Ohio, United States
Novo Nordisk Investigational Site
Kettering, Ohio, United States
Novo Nordisk Investigational Site
Mason, Ohio, United States
Novo Nordisk Investigational Site
Maumee, Ohio, United States
Novo Nordisk Investigational Site
Oklahoma City, Oklahoma, United States
Novo Nordisk Investigational Site
Beaver, Pennsylvania, United States
Novo Nordisk Investigational Site
Bridgeville, Pennsylvania, United States
Novo Nordisk Investigational Site
Norristown, Pennsylvania, United States
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, United States
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, United States
Novo Nordisk Investigational Site
Pittsburgh, Pennsylvania, United States
Novo Nordisk Investigational Site
Pittsburgh, Pennsylvania, United States
Novo Nordisk Investigational Site
East Providence, Rhode Island, United States
Novo Nordisk Investigational Site
Columbia, South Carolina, United States
Novo Nordisk Investigational Site
Greer, South Carolina, United States
Novo Nordisk Investigational Site
Pelzer, South Carolina, United States
Novo Nordisk Investigational Site
Simpsonville, South Carolina, United States
Novo Nordisk Investigational Site
Spartanburg, South Carolina, United States
Novo Nordisk Investigational Site
Taylors, South Carolina, United States
Novo Nordisk Investigational Site
Chattanooga, Tennessee, United States
Novo Nordisk Investigational Site
Chattanooga, Tennessee, United States
Novo Nordisk Investigational Site
Kingsport, Tennessee, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
DeSoto, Texas, United States
Novo Nordisk Investigational Site
Fort Worth, Texas, United States
Novo Nordisk Investigational Site
Houston, Texas, United States
Novo Nordisk Investigational Site
Houston, Texas, United States
Novo Nordisk Investigational Site
Houston, Texas, United States
Novo Nordisk Investigational Site
Irving, Texas, United States
Novo Nordisk Investigational Site
Killeen, Texas, United States
Novo Nordisk Investigational Site
Lubbock, Texas, United States
Novo Nordisk Investigational Site
San Antonio, Texas, United States
Novo Nordisk Investigational Site
San Antonio, Texas, United States
Novo Nordisk Investigational Site
Sugar Land, Texas, United States
Novo Nordisk Investigational Site
Ogden, Utah, United States
Novo Nordisk Investigational Site
Salt Lake City, Utah, United States
Novo Nordisk Investigational Site
St. George, Utah, United States
Novo Nordisk Investigational Site
Burke, Virginia, United States
Novo Nordisk Investigational Site
Manassas, Virginia, United States
Novo Nordisk Investigational Site
Newport News, Virginia, United States
Novo Nordisk Investigational Site
Virginia Beach, Virginia, United States
Novo Nordisk Investigational Site
Spokane, Washington, United States
Novo Nordisk Investigational Site
Milwaukee, Wisconsin, United States
Novo Nordisk Investigational Site
Broadmeadow, New South Wales, Australia
Novo Nordisk Investigational Site
Camperdown, New South Wales, Australia
Novo Nordisk Investigational Site
Coffs Harbour, New South Wales, Australia
Novo Nordisk Investigational Site
Penrith, New South Wales, Australia
Novo Nordisk Investigational Site
Meadowbrook, Queensland, Australia
Novo Nordisk Investigational Site
Keswick, South Australia, Australia
Novo Nordisk Investigational Site
East Ringwood, Victoria, Australia
Novo Nordisk Investigational Site
Melbourne, Victoria, Australia
Novo Nordisk Investigational Site
Edmonton, Alberta, Canada
Novo Nordisk Investigational Site
Chilliwack, British Columbia, Canada
Novo Nordisk Investigational Site
Vancouver, British Columbia, Canada
Novo Nordisk Investigational Site
Winnipeg, Manitoba, Canada
Novo Nordisk Investigational Site
Brampton, Ontario, Canada
Novo Nordisk Investigational Site
Burlington, Ontario, Canada
Novo Nordisk Investigational Site
Cornwall, Ontario, Canada
Novo Nordisk Investigational Site
Hamilton, Ontario, Canada
Novo Nordisk Investigational Site
Hamilton, Ontario, Canada
Novo Nordisk Investigational Site
Mississauga, Ontario, Canada
Novo Nordisk Investigational Site
Toronto, Ontario, Canada
Novo Nordisk Investigational Site
Drummondville, Quebec, Canada
Novo Nordisk Investigational Site
Laval, Quebec, Canada
Novo Nordisk Investigational Site
Québec, , Canada
Novo Nordisk Investigational Site
Québec, , Canada
Novo Nordisk Investigational Site
Hanko, , Finland
Novo Nordisk Investigational Site
Helsinki, , Finland
Novo Nordisk Investigational Site
Imatra, , Finland
Novo Nordisk Investigational Site
Kokkola, , Finland
Novo Nordisk Investigational Site
Oulu, , Finland
Novo Nordisk Investigational Site
Bad Neuenahr-Ahrweiler, , Germany
Novo Nordisk Investigational Site
Eisenach, , Germany
Novo Nordisk Investigational Site
Esslingen am Neckar, , Germany
Novo Nordisk Investigational Site
Frankfurt, , Germany
Novo Nordisk Investigational Site
Grevenbroich, , Germany
Novo Nordisk Investigational Site
Hamburg, , Germany
Novo Nordisk Investigational Site
Herrenberg, , Germany
Novo Nordisk Investigational Site
Hohenmölsen, , Germany
Novo Nordisk Investigational Site
Münster, , Germany
Novo Nordisk Investigational Site
Oldenburg, , Germany
Novo Nordisk Investigational Site
Pohlheim, , Germany
Novo Nordisk Investigational Site
Rehburg-Loccum, , Germany
Novo Nordisk Investigational Site
Rehlingen-Siersburg, , Germany
Novo Nordisk Investigational Site
Stuttgart, , Germany
Novo Nordisk Investigational Site
Budapest, , Hungary
Novo Nordisk Investigational Site
Budapest, , Hungary
Novo Nordisk Investigational Site
Debrecen, , Hungary
Novo Nordisk Investigational Site
Eger, , Hungary
Novo Nordisk Investigational Site
Gyula, , Hungary
Novo Nordisk Investigational Site
Pécs, , Hungary
Novo Nordisk Investigational Site
Szeged, , Hungary
Novo Nordisk Investigational Site
Ahmedabad, Gujarat, India
Novo Nordisk Investigational Site
Gurgaon, Haryana, India
Novo Nordisk Investigational Site
Bangalore, Karnataka, India
Novo Nordisk Investigational Site
Bangalore, Karnataka, India
Novo Nordisk Investigational Site
Kochi, Kerala, India
Novo Nordisk Investigational Site
Kochi, Kerala, India
Novo Nordisk Investigational Site
Thiruvanathapuram, Kerala, India
Novo Nordisk Investigational Site
Trivandrum, Kerala, India
Novo Nordisk Investigational Site
Indore, Madhya Pradesh, India
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India
Novo Nordisk Investigational Site
Pune, Maharashtra, India
Novo Nordisk Investigational Site
Bhubaneswar, Odisha, India
Novo Nordisk Investigational Site
Jaipur, Rajasthan, India
Novo Nordisk Investigational Site
Jaipur, Rajasthan, India
Novo Nordisk Investigational Site
Chennai, Tamil Nadu, India
Novo Nordisk Investigational Site
Chennai, Tamil Nadu, India
Novo Nordisk Investigational Site
Trichy, Tamil Nadu, India
Novo Nordisk Investigational Site
Kolkata, West Bengal, India
Novo Nordisk Investigational Site
Hyderabad, , India
Novo Nordisk Investigational Site
Kolkata, , India
Novo Nordisk Investigational Site
Patna, , India
Novo Nordisk Investigational Site
Pune, , India
Novo Nordisk Investigational Site
Dublin, , Ireland
Novo Nordisk Investigational Site
Galway, , Ireland
Novo Nordisk Investigational Site
Cosenza, , Italy
Novo Nordisk Investigational Site
Forlì, , Italy
Novo Nordisk Investigational Site
Monserrato, Cagliari, , Italy
Novo Nordisk Investigational Site
Novara, , Italy
Novo Nordisk Investigational Site
Olbia, , Italy
Novo Nordisk Investigational Site
Palermo, , Italy
Novo Nordisk Investigational Site
Siena, , Italy
Novo Nordisk Investigational Site
Torino, , Italy
Novo Nordisk Investigational Site
Cheras, , Malaysia
Novo Nordisk Investigational Site
George Town, , Malaysia
Novo Nordisk Investigational Site
Kota Bharu, Kelantan, , Malaysia
Novo Nordisk Investigational Site
Pulau Pinang, , Malaysia
Novo Nordisk Investigational Site
Putrajaya, , Malaysia
Novo Nordisk Investigational Site
Seremban, , Malaysia
Novo Nordisk Investigational Site
Guadalajara, Jalisco, Mexico
Novo Nordisk Investigational Site
Monterrey, Nuevo León, Mexico
Novo Nordisk Investigational Site
San Juan, , Puerto Rico
Novo Nordisk Investigational Site
Kursk, , Russia
Novo Nordisk Investigational Site
Moscow, , Russia
Novo Nordisk Investigational Site
Moscow, , Russia
Novo Nordisk Investigational Site
Penza, , Russia
Novo Nordisk Investigational Site
Saint Petersburg, , Russia
Novo Nordisk Investigational Site
Saint Petersburg, , Russia
Novo Nordisk Investigational Site
Saint Petersburg, , Russia
Novo Nordisk Investigational Site
Saratov, , Russia
Novo Nordisk Investigational Site
Stavropol, , Russia
Novo Nordisk Investigational Site
Voronezh, , Russia
Novo Nordisk Investigational Site
Vsevolozhsk, , Russia
Novo Nordisk Investigational Site
Singapore, , Singapore
Novo Nordisk Investigational Site
Singapore, , Singapore
Novo Nordisk Investigational Site
Singapore, , Singapore
Novo Nordisk Investigational Site
Bratislava, , Slovakia
Novo Nordisk Investigational Site
Lučenec, , Slovakia
Novo Nordisk Investigational Site
Moldava nad Bodvou, , Slovakia
Novo Nordisk Investigational Site
Nové Zámky, , Slovakia
Novo Nordisk Investigational Site
Port Elizabeth, Eastern Cape, South Africa
Novo Nordisk Investigational Site
Bloemfontein, Free State, South Africa
Novo Nordisk Investigational Site
Johannesburg, Gauteng, South Africa
Novo Nordisk Investigational Site
Johannesburg, Gauteng, South Africa
Novo Nordisk Investigational Site
Johannesburg, Gauteng, South Africa
Novo Nordisk Investigational Site
Johannesburg, Gauteng, South Africa
Novo Nordisk Investigational Site
Vaderbijlpark, Gauteng, South Africa
Novo Nordisk Investigational Site
Durban, KwaZulu-Natal, South Africa
Novo Nordisk Investigational Site
Durban, KwaZulu-Natal, South Africa
Novo Nordisk Investigational Site
Durban, KwaZulu-Natal, South Africa
Novo Nordisk Investigational Site
Durban, KwaZulu-Natal, South Africa
Novo Nordisk Investigational Site
eMkhomazi, KwaZulu-Natal, South Africa
Novo Nordisk Investigational Site
Brits, North West, South Africa
Novo Nordisk Investigational Site
Cape Town, Western Cape, South Africa
Novo Nordisk Investigational Site
A Coruña, , Spain
Novo Nordisk Investigational Site
Almería, , Spain
Novo Nordisk Investigational Site
Granada, , Spain
Novo Nordisk Investigational Site
Partida de Bacarot, , Spain
Novo Nordisk Investigational Site
Seville, , Spain
Novo Nordisk Investigational Site
Seville, , Spain
Novo Nordisk Investigational Site
Valencia, , Spain
Novo Nordisk Investigational Site
Valladolid, , Spain
Novo Nordisk Investigational Site
Taichung, , Taiwan
Novo Nordisk Investigational Site
Tainan City, , Taiwan
Novo Nordisk Investigational Site
Taipei, , Taiwan
Novo Nordisk Investigational Site
Taoyuan District, , Taiwan
Novo Nordisk Investigational Site
Bangkok, , Thailand
Novo Nordisk Investigational Site
Bangkok, , Thailand
Novo Nordisk Investigational Site
Bangkoknoi, Bangkok, , Thailand
Novo Nordisk Investigational Site
Chiang Mai, , Thailand
Novo Nordisk Investigational Site
Belfast, , United Kingdom
Novo Nordisk Investigational Site
Bury St Edmunds, , United Kingdom
Novo Nordisk Investigational Site
Carmarthen, , United Kingdom
Novo Nordisk Investigational Site
Dundee, , United Kingdom
Novo Nordisk Investigational Site
Edgbaston, Birmingham, , United Kingdom
Novo Nordisk Investigational Site
Fife, , United Kingdom
Novo Nordisk Investigational Site
Glasgow, , United Kingdom
Novo Nordisk Investigational Site
Gloucester, , United Kingdom
Novo Nordisk Investigational Site
Headington, , United Kingdom
Novo Nordisk Investigational Site
Lancaster, , United Kingdom
Novo Nordisk Investigational Site
Letchworth Garden City, , United Kingdom
Novo Nordisk Investigational Site
Llantrisant, , United Kingdom
Novo Nordisk Investigational Site
London, , United Kingdom
Novo Nordisk Investigational Site
St Helens, , United Kingdom
Novo Nordisk Investigational Site
Stevenage, , United Kingdom
Novo Nordisk Investigational Site
Weston-super-Mare, , United Kingdom
Novo Nordisk Investigational Site
Wrexham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Khunti K, Mohan V, Jain SM, Boesgaard TW, Begtrup K, Sethi B. Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program. Diabetes Ther. 2017 Jun;8(3):673-682. doi: 10.1007/s13300-017-0252-9. Epub 2017 Mar 22.
Holst JJ, Buse JB, Rodbard HW, Linjawi S, Woo VC, Boesgaard TW, Kvist K, Gough SC. IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. J Diabetes Sci Technol. 2015 Oct 6;10(2):389-97. doi: 10.1177/1932296815610124.
Vilsboll T, Vora J, Jarlov H, Kvist K, Blonde L. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Clin Drug Investig. 2016 Apr;36(4):293-303. doi: 10.1007/s40261-016-0376-0.
Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1.
Gough SC, Bode BW, Woo VC, Rodbard HW, Linjawi S, Zacho M, Reiter PD, Buse JB. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab. 2015 Oct;17(10):965-73. doi: 10.1111/dom.12498. Epub 2015 Jul 1.
Kapitza C, Bode B, Ingwersen SH, Jacobsen LV, Poulsen P. Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. J Clin Pharmacol. 2015 Dec;55(12):1369-77. doi: 10.1002/jcph.549. Epub 2015 Jul 14.
King AB, Philis-Tsimikas A, Kilpatrick ES, Langbakke IH, Begtrup K, Vilsboll T. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. Diabetes Technol Ther. 2017 Apr;19(4):255-264. doi: 10.1089/dia.2016.0405. Epub 2017 Mar 10.
Norwood P, Chen R, Jaeckel E, Lingvay I, Jarlov H, Lehmann L, Heller S. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Diabetes Obes Metab. 2017 Nov;19(11):1562-1569. doi: 10.1111/dom.12972. Epub 2017 Jul 10.
Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1119-1174
Identifier Type: OTHER
Identifier Source: secondary_id
2010-021560-15
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
NN9068-3697
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.